{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:21:40Z","timestamp":1781263300112,"version":"3.54.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The objectives of this study were to evaluate whether dose to the vasculature is associated with local control after surgery in patients with borderline resectable (BLR) and resectable pancreatic cancer (PCA) receiving neoadjuvant radiation therapy (RT) and to identify a dose threshold for clinical use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with BLR and resectable PCA treated with neoadjuvant RT were retrospectively reviewed. During this period, the institutional paradigm shifted from standard fractionation to hypofractionation\/stereotactic body radiation therapy (SBRT). A vasculature clinical target volume (Vasc CTV) was contoured for each patient and defined as a 5-mm margin around the superior mesenteric artery (SMA) from its origin to the pancreatic head, the celiac artery from its origin to the level of the trifurcation and any involved vein. The Vasc CTV D95 was normalized to a 2-Gy equivalent dose to determine the optimal dose associated with optimal local failure-free survival (LFFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-seven patients were included in the analysis. A Vasc CTV D95 of 32.7 Gy was the optimal cutoff for LFFS. Patients with Vasc CTV D95 Equivalent dose in 2 Gy per fraction (EQD2) &amp;gt;32.7 Gy had significantly longer LFFS compared to patients with Vasc CTV D95 EQD2 \u226432.7 Gy at 12 months (91% vs. 51%, respectively) and 24 months (86% vs. 12%, respectively). The median disease-free survival (DFS) for patients with EQD2 &amp;gt;32.7 Gy was 30.4 months compared to 14.0 months in patients with EQD2 \u226432.7 Gy (p = 0.01). There was no significant difference in overall survival (OS) between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>During neoadjuvant treatment, dose to the Vasc CTV is associated with durability of local control (LC) after resection and should be intentionally included in the treatment volume with an EQD2 goal of 31\u201333 Gy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.906484","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T05:48:35Z","timestamp":1661924915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation"],"prefix":"10.3389","volume":"12","author":[{"given":"Bailey","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Barrord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan A.","family":"Wages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickaela","family":"Sudhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Kharofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2007.12.017","article-title":"Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma","volume":"195","author":"Brown","year":"2008","journal-title":"Am J Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1385\/IJGC","article-title":"Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas","volume":"34","author":"Sasson","year":"2003","journal-title":"Int J Gastrointest Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.09.010","article-title":"Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer","volume":"113","author":"Kharofa","year":"2014","journal-title":"Radiother Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8642","article-title":"Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Varadhachary","year":"2008","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1200\/JCO.2021.39.15_suppl.4016","article-title":"Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial","volume":"39","author":"Van Eijck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: A new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"B12","article-title":"Neural invasion in pancreatic carcinoma","volume":"1","author":"Liu","year":"2002","journal-title":"Hepatobil Pancreat Dis Int HBPD Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2017.01.007","article-title":"The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - a systematic review and meta-analysis","volume":"26","author":"Schorn","year":"2017","journal-title":"Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000726","article-title":"Comparison of radiation treatment volumes for borderline resectable pancreatic cancer in contemporary clinical trials","volume":"43","author":"Bluemel","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.01.075","article-title":"Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: Implications of target volume design","volume":"104","author":"Zhu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma: SBRT for unresectable pancreatic cancer","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.gastro.2013.11.004","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the society of abdominal radiology and the American pancreatic Association1","volume":"146","author":"Al-Hawary","year":"2014","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.03.034","article-title":"A phase 1\/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma","volume":"89","author":"Hong","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijrobp.2021.07.1698","article-title":"Pancreatic sterotactic body radiation therapy with or without hypofractionated elective nodal irradiation","volume":"112","author":"Miller","year":"2021","journal-title":"Int J Radiat Oncol Bio Phys"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.01.2022","article-title":"Radiation therapy oncology group consensus panel guidelines for the delineation of clinical target volume in the postoperative treatment of pancreatic head cancer","volume":"83","author":"Goodman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30117","article-title":"Impact of hypofractionated and standard fractionated chemoradiation prior to pancreatoduodenectomy for pancreatic ductal adenocarcinoma","volume":"122","author":"Cloyd","year":"2016","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: A phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.906484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T05:48:37Z","timestamp":1661924917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.906484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":28,"alternative-id":["10.3389\/fonc.2022.906484"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.906484","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"906484"}}